An Anthem Blue Cross subscriber is suing the health insurer, alleging she was wrongfully denied coverage for Zepbound for weight management because she was no longer considered morbidly obese. Alicia ...

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...

Trump administration demands lower prices in the U.S., forcing the pharmaceutical company to raise them in other markets ...

One company remains at the forefront of the AI frenzy, whereas the other has seen insiders dive in post-earnings.

Texas is seeking more than $1 million from Eli Lilly in a lawsuit accusing the drugmaker of persuading physicians to prescribe its medications, including GLP-1s such as Mounjaro and Zepbound, through ...

GLP-1 receptor agonists like semaglutide and the dual GIP/GLP-1 agonist tirzepatide mimic naturally occurring hormones that regulate blood sugar, appetite, and digestion. GLP-1 (glucagon-like ...

Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for G protein ...

The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa, marking its debut in Africa and stepping up competition with Eli Lilly's Mounjaro launched in the country eight ...

More than 1 in 4 adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the ...

CHICAGO — New research is showing certain weight loss drugs could be linked to eye related issues. A couple studies published in the Journal of the American Medical Association looks into Ozempic, ...